court – Talk Bio

Federal Circuit ruling allows Amgen’s Eylea biosimilar to stay on the market

1 month ago talkbio0Tagged amgen, Amgen 's, court, Eylea, Eylea biosimilar, Federal Circuit, Market, Pavblu, Regeneron

Market, Amgen ‘s, Pavblu, Amgen, Eylea biosimilar, Regeneron, Federal Circuit, court, Eylea

Legal Battle Erupts as Deerfield Accuses Alcon of Obstructing Aurion Biotech’s IPO Plans

2 months ago talkbio0Tagged Alcon, biotech, biotech industry, Bovichtus, Chancery, Corporate, court, Deerfield Management, Delaware, governance, IPO, Legal, Public Offering, research, shareholder

Aurion Biotech, Alcon Research, Deerfield Management , Initial Public Offering (IPO), Legal dispute, Biotech industry, Corporate governance, Shareholder rights, Delaware Court of Chancery

Trump’s Second Term: Mifepristone Battle Looms as Early Test of Abortion Stance

3 months ago talkbio0Tagged court, mifepristone, Reproduction, Supreme, Transplant Registry Unified Management Program, United States Food and Drug Administration, Unspecified Abortion

Mifepristone, abortion, Trump, second term, reproductive rights, FDA, Supreme Court

Supreme Court Declines to Review PhRMA’s Challenge to Arkansas’ 340B Contract Pharmacy Law

5 months ago talkbio0Tagged 1103, Arkansas, Contract agreement, court, drug price, federal, Pharmacy facility, PhRMA, Programs - Publication Format, Supreme

340B Program, Arkansas Act 1103, PhRMA, Supreme Court, Contract Pharmacies, Drug Pricing, Federal Preemption

Federal Court Dismisses Novartis’ Challenge to Inflation Reduction Act, Marking Sixth Win for Government

6 months ago talkbio0Tagged court, Drug Industry, drug price, federal, Government, Inflation, Ira (eukaryote), lawsuit, Medicare, Negotiation Program, Novartis, victory

Inflation Reduction Act, IRA lawsuit, Novartis, Medicare Drug Price Negotiation Program, federal court, pharmaceutical industry, government victory

European Court Suspends EC’s Decision to Revoke Ocaliva’s Marketing Authorization

8 months ago talkbio0Tagged Advanz Pharma, authorization, Biliary Cholangitis, court, Decision, EC, European (ethnic group), Ocaliva, Primary Biliary Cholangitis

Ocaliva, European Court, EC decision, marketing authorization, primary biliary cholangitis, PBC, Advanz Pharma

The Post-Chevron Regulatory Landscape: Implications for the FDA and Healthcare Industry

8 months ago talkbio0Tagged Administrative procedure, Boards (medical device), Chevron Deference, Corner Post, court, Federal Reserve System, Governors, Healthcare Industry, judicial, Landscapes, Legal, Loper Bright Enterprises, Raimondo, regulatory, Supreme, United States Food and Drug Administration

Chevron deference, FDA, regulatory landscape, healthcare industry, Supreme Court ruling, Loper Bright Enterprises v. Raimondo, Corner Post, Inc. v. Board of Governors of the Federal Reserve System, Administrative Procedure Act (APA), judicial scrutiny, legal challenges, regulatory implications.